Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
6 studies found for:    BONE MARROW FAILURE, FAMILIAL
Show Display Options
Rank Status Study
1 Recruiting CD34+ Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation for Non-Malignant Disease
Conditions: Bone Marrow Failure Syndrome;   Severe Aplastic Anemia;   Severe Congenital Neutropenia;   Amegakaryocytic Thrombocytopenia;   Diamond-Blackfan Anemia;   Schwachman Diamond Syndrome;   Primary Immunodeficiency Syndromes;   Acquired Immunodeficiency Syndromes;   Histiocytic Syndrome;   Familial Hemophagocytic Lymphocytosis;   Lymphohistiocytosis;   Macrophage Activation Syndrome;   Langerhans Cell Histiocytosis (LCH);   Hemoglobinopathies;   Sickle Cell Disease;   Sickle Cell-beta-thalassemia
Intervention: Biological: CliniMacs (PLUS) Reagent System
2 Recruiting CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant
Conditions: Leukemia;   Lymphoma;   Bone Marrow Failure;   Immunodeficiencies;   Histiocytosis
Interventions: Drug: Full Intensity with TBI;   Drug: Full Intensity;   Drug: Reduced Intensity;   Drug: Reduced Intensity (Fanconi)
3 Recruiting Donor Stem Cell Transplant After Busulfan, Fludarabine, Methylprednisolone, and Antithymocyte Globulin in Treating Patients With Bone Marrow Failure Syndrome
Conditions: Leukemia;   Myelodysplastic Syndromes;   Nonmalignant Neoplasm;   Paroxysmal Nocturnal Hemoglobinuria
Intervention: Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation
4 Recruiting Cancer in Inherited Bone Marrow Failure Syndromes
Conditions: Fanconi's Anemia;   Anemia, Diamond Blackfan;   Dyskeratosis Congenital;   Thrombocytopenia;   Neutropenia
Intervention:
5 Recruiting CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant
Conditions: Chronic Myeloid Leukemia (CML);   Acute Myelogenous Leukemia (AML);;   Myelodysplastic Syndrome (MDS);;   Juvenile Myelomonocytic Leukemia (JMML);;   Acute Lymphoblastic Leukemia (ALL);;   Lymphoma (Hodgkin's and Non-Hodgkin's)
Interventions: Device: CliniMACS CD34+ Reagent System;   Drug: Thiotepa;   Drug: Cyclophosphamide;   Drug: Alemtuzumab;   Drug: Tacrolimus;   Drug: Melphalan;   Drug: Busulfan;   Drug: Fludarabine
6 Completed Donor Natural Killer Cell Infusion in Preventing Relapse or Graft Failure in Patients Who Have Undergone Donor Bone Marrow Transplant
Condition: Cancer
Intervention: Biological: therapeutic allogeneic lymphocytes

Indicates status has not been verified in more than two years